Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis

Detalhes bibliográficos
Autor(a) principal: Hundarova,Kristina
Data de Publicação: 2023
Outros Autores: Frutuoso,Cristina, Águas,Fernanda, Andrade,Cláudia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302023009000196
Resumo: Abstract Introduction: The lymph node status is of utmost importance in endometrial cancer staging. However, the therapeutic importance of systematic lymphadenectomy was not proven, thus the sentinel lymph node biopsy (SLNB) is emerging as an alternative to classic surgical staging procedure. We aimed to evaluate the feasibility of SLNB in clinical early-stage endometrial cancer, at a university-affiliated teaching hospital. Material and Methods: Retrospective, single-centre, observational analysis, including patients with clinical stage I or II endometrial cancer, submitted to minimally invasive primary surgery. Patients underwent sentinel lymph node mapping with indocyanine green dye, after cervical injection, from September 2019 to September 2022. The ultra-staging protocol was followed. The map rate, sensitivity, negative predictive value, and false negatives were calculated. Results: Fifty-six patients met the inclusion criteria. The overall and bilateral detection rate was o 96.4% and 80.3%, respectively. After SLNB, complete pelvic lymphadenectomy was performed in 33.9% of patients. Lymphatic metastases were found in 6 (10.7%) cases, all of them in sentinel lymph node sampling. Four patients, with pre-operative low-risk of recurrence, had bilateral SLNB and the histopathological evaluation revealed micrometastases. Two patients, who underwent pelvic lymphadenectomy, had macrometastases. The sensitivity and negative predictive value of SLNB were 100%, with a false negative rate of 0%. Comparative analysis between the groups with a low-risk of recurrence, that underwent SLNB alone, and intermediate/high-risk groups, that performed systematic lymphadenectomy, showed a significant difference in surgery duration, hospital stay, and complication rate (higher in the systematic lymphadenectomy group). There were no adverse effects related to the indocyanine green injection. Conclusion: SLNB is a safe procedure, with a high detection rate and sensitivity, avoiding the morbidities related to systematic lymphadenectomy. The implementation of the ultra-staging protocol is crucial to allow the diagnosis of the low-volume metastatic involvement, influencing the definitive staging of apparently low-risk patients.
id RCAP_155297574ee0d4d6d452340e11100c32
oai_identifier_str oai:scielo:S1646-58302023009000196
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre AnalysisEndometrial cancerSentinel lymph node biopsyIndocyanine greenMinimally invasive surgeryLymphadenectomyAbstract Introduction: The lymph node status is of utmost importance in endometrial cancer staging. However, the therapeutic importance of systematic lymphadenectomy was not proven, thus the sentinel lymph node biopsy (SLNB) is emerging as an alternative to classic surgical staging procedure. We aimed to evaluate the feasibility of SLNB in clinical early-stage endometrial cancer, at a university-affiliated teaching hospital. Material and Methods: Retrospective, single-centre, observational analysis, including patients with clinical stage I or II endometrial cancer, submitted to minimally invasive primary surgery. Patients underwent sentinel lymph node mapping with indocyanine green dye, after cervical injection, from September 2019 to September 2022. The ultra-staging protocol was followed. The map rate, sensitivity, negative predictive value, and false negatives were calculated. Results: Fifty-six patients met the inclusion criteria. The overall and bilateral detection rate was o 96.4% and 80.3%, respectively. After SLNB, complete pelvic lymphadenectomy was performed in 33.9% of patients. Lymphatic metastases were found in 6 (10.7%) cases, all of them in sentinel lymph node sampling. Four patients, with pre-operative low-risk of recurrence, had bilateral SLNB and the histopathological evaluation revealed micrometastases. Two patients, who underwent pelvic lymphadenectomy, had macrometastases. The sensitivity and negative predictive value of SLNB were 100%, with a false negative rate of 0%. Comparative analysis between the groups with a low-risk of recurrence, that underwent SLNB alone, and intermediate/high-risk groups, that performed systematic lymphadenectomy, showed a significant difference in surgery duration, hospital stay, and complication rate (higher in the systematic lymphadenectomy group). There were no adverse effects related to the indocyanine green injection. Conclusion: SLNB is a safe procedure, with a high detection rate and sensitivity, avoiding the morbidities related to systematic lymphadenectomy. The implementation of the ultra-staging protocol is crucial to allow the diagnosis of the low-volume metastatic involvement, influencing the definitive staging of apparently low-risk patients.Euromédice, Edições Médicas Lda.2023-09-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302023009000196Acta Obstétrica e Ginecológica Portuguesa v.17 n.3 2023reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302023009000196Hundarova,KristinaFrutuoso,CristinaÁguas,FernandaAndrade,Cláudiainfo:eu-repo/semantics/openAccess2024-02-06T17:22:01Zoai:scielo:S1646-58302023009000196Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:28:50.163410Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis
title Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis
spellingShingle Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis
Hundarova,Kristina
Endometrial cancer
Sentinel lymph node biopsy
Indocyanine green
Minimally invasive surgery
Lymphadenectomy
title_short Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis
title_full Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis
title_fullStr Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis
title_full_unstemmed Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis
title_sort Performance of Sentinel Lymph Node Mapping in Early-Stage Endometrial Cancer: A Single-Centre Analysis
author Hundarova,Kristina
author_facet Hundarova,Kristina
Frutuoso,Cristina
Águas,Fernanda
Andrade,Cláudia
author_role author
author2 Frutuoso,Cristina
Águas,Fernanda
Andrade,Cláudia
author2_role author
author
author
dc.contributor.author.fl_str_mv Hundarova,Kristina
Frutuoso,Cristina
Águas,Fernanda
Andrade,Cláudia
dc.subject.por.fl_str_mv Endometrial cancer
Sentinel lymph node biopsy
Indocyanine green
Minimally invasive surgery
Lymphadenectomy
topic Endometrial cancer
Sentinel lymph node biopsy
Indocyanine green
Minimally invasive surgery
Lymphadenectomy
description Abstract Introduction: The lymph node status is of utmost importance in endometrial cancer staging. However, the therapeutic importance of systematic lymphadenectomy was not proven, thus the sentinel lymph node biopsy (SLNB) is emerging as an alternative to classic surgical staging procedure. We aimed to evaluate the feasibility of SLNB in clinical early-stage endometrial cancer, at a university-affiliated teaching hospital. Material and Methods: Retrospective, single-centre, observational analysis, including patients with clinical stage I or II endometrial cancer, submitted to minimally invasive primary surgery. Patients underwent sentinel lymph node mapping with indocyanine green dye, after cervical injection, from September 2019 to September 2022. The ultra-staging protocol was followed. The map rate, sensitivity, negative predictive value, and false negatives were calculated. Results: Fifty-six patients met the inclusion criteria. The overall and bilateral detection rate was o 96.4% and 80.3%, respectively. After SLNB, complete pelvic lymphadenectomy was performed in 33.9% of patients. Lymphatic metastases were found in 6 (10.7%) cases, all of them in sentinel lymph node sampling. Four patients, with pre-operative low-risk of recurrence, had bilateral SLNB and the histopathological evaluation revealed micrometastases. Two patients, who underwent pelvic lymphadenectomy, had macrometastases. The sensitivity and negative predictive value of SLNB were 100%, with a false negative rate of 0%. Comparative analysis between the groups with a low-risk of recurrence, that underwent SLNB alone, and intermediate/high-risk groups, that performed systematic lymphadenectomy, showed a significant difference in surgery duration, hospital stay, and complication rate (higher in the systematic lymphadenectomy group). There were no adverse effects related to the indocyanine green injection. Conclusion: SLNB is a safe procedure, with a high detection rate and sensitivity, avoiding the morbidities related to systematic lymphadenectomy. The implementation of the ultra-staging protocol is crucial to allow the diagnosis of the low-volume metastatic involvement, influencing the definitive staging of apparently low-risk patients.
publishDate 2023
dc.date.none.fl_str_mv 2023-09-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302023009000196
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302023009000196
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302023009000196
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Euromédice, Edições Médicas Lda.
publisher.none.fl_str_mv Euromédice, Edições Médicas Lda.
dc.source.none.fl_str_mv Acta Obstétrica e Ginecológica Portuguesa v.17 n.3 2023
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137357542195200